BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30948682)

  • 1. Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis.
    Huang Z; Lee PY; Yao X; Zheng S; Li T
    Pediatrics; 2019 May; 143(5):. PubMed ID: 30948682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
    Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D; O'Dell KM; Bandy JL; Boyce EG
    Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
    Tanaka Y; Yamaoka K
    Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
    Ruperto N; Brunner HI; Synoverska O; Ting TV; Mendoza CA; Spindler A; Vyzhga Y; Marzan K; Grebenkina L; Tirosh I; Imundo L; Jerath R; Kingsbury DJ; Sozeri B; Vora SS; Prahalad S; Zholobova E; Butbul Aviel Y; Chasnyk V; Lerman M; Nanda K; Schmeling H; Tory H; Uziel Y; Viola DO; Posner HB; Kanik KS; Wouters A; Chang C; Zhang R; Lazariciu I; Hsu MA; Suehiro RM; Martini A; Lovell DJ;
    Lancet; 2021 Nov; 398(10315):1984-1996. PubMed ID: 34767764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib for treatment of rheumatoid arthritis.
    Rakieh C; Conaghan PG
    Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
    Miserocchi E; Giuffrè C; Cornalba M; Pontikaki I; Cimaz R
    Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
    Ruperto N; Brunner HI; Zuber Z; Tzaribachev N; Kingsbury DJ; Foeldvari I; Horneff G; Smolewska E; Vehe RK; Hazra A; Wang R; Mebus CA; Alvey C; Lamba M; Krishnaswami S; Stock TC; Wang M; Suehiro R; Martini A; Lovell DJ; ;
    Pediatr Rheumatol Online J; 2017 Dec; 15(1):86. PubMed ID: 29282090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignancy and Janus Kinase Inhibition.
    Sivaraman P; Cohen SB
    Rheum Dis Clin North Am; 2017 Feb; 43(1):79-93. PubMed ID: 27890175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Disease: A Rare but Devastating Complication of Systemic Juvenile Idiopathic Arthritis and the Use of Tofacitinib as a Treatment.
    Kaplan MM; Cinel G; Çelikel E
    Arch Bronconeumol; 2024 Jun; 60(6):374-375. PubMed ID: 38402050
    [No Abstract]   [Full Text] [Related]  

  • 14. JAK inhibitors: A broadening approach in rheumatoid arthritis.
    Lam S
    Drugs Today (Barc); 2016 Aug; 52(8):467-469. PubMed ID: 27722215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
    Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
    Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
    Goodman SM; Springer B; Guyatt G; Abdel MP; Dasa V; George M; Gewurz-Singer O; Giles JT; Johnson B; Lee S; Mandl LA; Mont MA; Sculco P; Sporer S; Stryker L; Turgunbaev M; Brause B; Chen AF; Gililland J; Goodman M; Hurley-Rosenblatt A; Kirou K; Losina E; MacKenzie R; Michaud K; Mikuls T; Russell L; Sah A; Miller AS; Singh JA; Yates A
    Arthritis Rheumatol; 2017 Aug; 69(8):1538-1551. PubMed ID: 28620948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: A study from Bangladesh.
    Rahman MM; Laila K; Rahman SA
    Int J Rheum Dis; 2022 Jun; 25(6):678-684. PubMed ID: 35435319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib in psoriatic arthritis.
    Wang TS; Tsai TF
    Immunotherapy; 2017 Nov; 9(14):1153-1163. PubMed ID: 28967798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever.
    Gök K; Cengiz G; Erol K; Ozgocmen S
    Acta Reumatol Port; 2017; 42(1):88-90. PubMed ID: 28371574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.